Press release - 21/09/2012 Biomarkers for virus-induced cancer in the oropharynx Patients with oropharyngeal cancers have a more favorable prognosis if their tumors are caused by human papillomaviruses. Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and Heidelberg University Hospital have now identified biomarkers which enable them to differentiate cancer cases taking a favorable course from those with an unfavorable one. It may be possible to treat the two disease types…https://www.gesundheitsindustrie-bw.de/en/article/press-release/biomarkers-for-virus-induced-cancer-in-the-oropharynx
Press release - 07/08/2012 immatics announces publication of IMA901 cancer vaccine data in Nature Medicine immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that key data covering the scientific and clinical development of its lead cancer vaccine, IMA901, have been published in Nature Medicine. The paper highlights that renal cell carcinoma patients experience longer survival times when their immune system produces an immune response to…https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-announces-publication-of-ima901-cancer-vaccine-data-in-nature-medicine
Article - 16/07/2012 Laupheim to become an international forum for biomanufacturing The 2nd Laupheimer Zelltage conference organized by Rentschler Biotechnologie GmbH in Laupheim on 11th and 12th June 2012 focused on “Bioprocess light”. Twelve experts from applied research institutions and biotech companies from Germany and abroad provided the 200 or so guests with information on how modern bioproduction methods can be made simpler, more robust, cheaper, more reliable and hence more competitive.https://www.gesundheitsindustrie-bw.de/en/article/news/laupheim-to-become-an-international-forum-for-biomanufacturing
Dossier - 18/06/2012 Biobanks – treasure chests for biomedical research Biobanking is still a very specialist subject. The Research Committee at the German Bundestag, the Office of Technology Assessment at the German Bundestag and the German Ethics Council are all interested in this biomedical research tool, which is both necessary and meaningful. However, opinions with regard to the ethical, legal and technical approach to biobanks differ. Since March 2012 it has become absolutely clear that Germany will not pass a…https://www.gesundheitsindustrie-bw.de/en/article/dossier/biobanks-treasure-chests-for-biomedical-research
Article - 18/06/2012 National biobanks for scientific research Biobanks are of key importance for biomedical research and for improving diagnostics and therapies involving new biomarkers. The German Federal Ministry of Education and Research is funding the National Biobank Initiative with a total of around 18 million euros. The initiative aims to standardize and combine the resources of five model locations, including the BioMaterialBank Heidelberg which integrates the tissue bank of the National Centre for…https://www.gesundheitsindustrie-bw.de/en/article/news/national-biobanks-for-scientific-research
Article - 05/06/2012 Max Planck Director Izaurralde honored for groundbreaking research Professor Dr. Elisa Izaurralde has made important contributions to the field of RNA biology in recent years. The managing director of the Max Planck Institute for Developmental Biology in Tübingen explores the complex mechanisms of cellular gene regulation. For her work on mRNA regulation she has now been honored with the prestigious Ernst Jung Prize for Medicine.https://www.gesundheitsindustrie-bw.de/en/article/news/max-planck-director-izaurralde-honored-for-groundbreaking-research
Article - 30/04/2012 German Cardiac Society meeting 2012 - Medicine for sick hearts The recent German Cardiac Society meeting in Mannheim in April 2012 focused on the latest findings related to the prognosis, diagnosis and therapy of heart diseases. While great progress has been made in the therapy of disease symptoms, it will still take a long time before gene and stem cell therapies that target the causes of disease find their way into clinical application. The conference also presented the new German Centre for Cardiovascular…https://www.gesundheitsindustrie-bw.de/en/article/news/german-cardiac-society-meeting-2012-medicine-for-sick-hearts
Article - 16/04/2012 Christine von Arnim: the Alzheimer's researcher has a good overall view “Memory is one of the most exciting research topics I know because it is so close to human reality”, says Christine von Arnim. The Alzheimer’s disease researcher from the University of Ulm is not the only researcher who is intrigued by the philosophy behind the research and interested in far more than just atomistic approaches. The young neurologist covers the entire field of Alzheimer’s research, from experimental laboratory research to patient…https://www.gesundheitsindustrie-bw.de/en/article/news/christine-von-arnim-the-alzheimer-s-researcher-has-a-good-overall-view
Article - 19/03/2012 When the “second brain” fails – therapeutic options from the field of regenerative medicine Researchers from the Center for Regenerative Biology and Medicine ZRM in Tübingen are focused on the enteric nervous system of the gastrointestinal tract with the aim of developing cell-based therapies for the treatment of bowel diseases. The researchers are working with local partners in a BMBF-funded project that is seeking to develop therapies for Hirschsprung’s disease.https://www.gesundheitsindustrie-bw.de/en/article/news/when-the-second-brain-fails-therapeutic-options-from-the-field-of-regenerative-medicine
Press release - 10/01/2012 Apogenix receives additional 2.3 million Euros BMBF grant as partner of the biotech cluster Rhine-Neckar The biopharmaceutical company Apogenix GmbH today announced that it has received an additional € 2.3 million BMBF grant (German Federal Ministry of Education and Research) for the further advancement of its lead substance APG101. Apogenix will use the proceeds to develop APG101 for the treatment of myelodysplastic syndromes (MDS). More specifically, the grant will be used for the production of clinical material and for the development of a…https://www.gesundheitsindustrie-bw.de/en/article/press-release/apogenix-receives-additional-2-3-million-euros-bmbf-grant-as-partner-of-the-biotech-cluster-rhine-ne
Article - 09/01/2012 Biomarkers to combat lung cancer A biomarker-driven personalised therapeutic approach to lung cancer is possible – this is the conclusion reached by the BATTLE trial. The preliminary results of the trial were summarised by scientists from the Thoraxklinik at Heidelberg University Hospital in the May 2011 issue of “Clinical Investigation”.https://www.gesundheitsindustrie-bw.de/en/article/news/biomarkers-to-combat-lung-cancer
Article - 19/12/2011 Lenhard Rudolph prepares four biomarkers for clinical application Lenhard Rudolph’s biomarker quartet is extremely promising in terms of progressing medical and clinical treatment in ageing societies. The quartet - EF-1 alpha, Chi3L3, CRAMP and OP 18 – is made up of four proteins that can potentially be used as biomarkers. Specific concentrations of these molecules in human blood provide information on the biological age and renewal capacity of the tissue and organs of patients. The biomarker quartet also…https://www.gesundheitsindustrie-bw.de/en/article/news/lenhard-rudolph-prepares-four-biomarkers-for-clinical-application
Article - 12/12/2011 Rheumatoid arthritis biomarkers A plethora of biomarkers is available for the early diagnosis of rheumatoid arthritis and associated tissue damage and disorders. In addition, new biomarkers that improve the diagnosis and treatment of patients suffering from this common destructive autoimmune disease are constantly being discovered.https://www.gesundheitsindustrie-bw.de/en/article/news/rheumatoid-arthritis-biomarkers
Article - 12/12/2011 The detection of inflammation in “single-use laboratories“ Depression, rheumatism, sickle cell anaemia – elevated levels of substance P in blood plasma might be an alarm signal. The molecule plays an important role in generating an inflammatory response. Commercially available tests involving microtitre plates are time-consuming and expensive. Dr. Hüseyin Bakirci and his team from the Department of Microsystems Engineering (IMTEK) at the University of Freiburg have developed a chip the size of a…https://www.gesundheitsindustrie-bw.de/en/article/news/the-detection-of-inflammation-in-single-use-laboratories
Article - 12/12/2011 Comprehensive Biomarker Center GmbH – next-generation biomarkers Biomarker research has moved on from proteins to nucleic acids where one of the main priorities is the use of microRNA expression profiles. The Heidelberg-based biotech company Comprehensive Biomarker Center GmbH (CBC, formerly febit) has state-of-the-art technologies and the skills and knowledge to advance the development of new nucleic acid biomarkers for complex diseases in cooperation with partners from research and industry. https://www.gesundheitsindustrie-bw.de/en/article/news/comprehensive-biomarker-center-gmbh-next-generation-biomarkers
Dossier - 12/12/2011 Development of new molecular biomarkers Biomarkers are playing an increasing role in drug discovery and development. They can be used as molecular indicators for diseases and disease risks as well as for monitoring the effectiveness of therapy. Highly specific molecular biomarkers are being identified using state-of-the-art technologies from the fields of genomics, proteomics and metabolomics.https://www.gesundheitsindustrie-bw.de/en/article/dossier/development-of-new-molecular-biomarkers
Article - 14/11/2011 Does cloudy apple juice prevent colon cancer? The likelihood of developing colon cancer very much depends on dietary factors. Foods and nutrients with antioxidative and anti-inflammatory properties have been found to reduce the likelihood of developing this kind of cancer. Research done by scientists from the Karlsruhe-based Max Rubner-Institut suggests that cloudy apple juice can prevent colon cancer. However, little is yet known about the molecular relationships between diet and disease.https://www.gesundheitsindustrie-bw.de/en/article/news/does-cloudy-apple-juice-prevent-colon-cancer
Press release - 25/10/2011 Research Initiative to Combat Cell Ageing Insilico Biotechnology and its partners have started a joint large-scale research project to study how reactive oxygen species trigger ageing processes on the cell and tissue level and how to prevent these if possible. Biomarkers will be used to expose the processes and molecular target structures will be identified which can be targeted with active agents to delay ageing.https://www.gesundheitsindustrie-bw.de/en/article/press-release/research-initiative-to-combat-cell-ageing
Press release - 20/07/2011 Roche acquires mtm laboratories AG, expanding offering in cervical cancer Roche announced on July 19th that it has signed an agreement under which it will acquire 100 percent of mtm laboratories AG (mtm), a privately-held company based in Heidelberg, Germany. mtm is a global leader in developing in vitro diagnostics with a focus on early detection and diagnosis of cervical cancer, the largest early detection market in oncology. mtm will become part of Roche’s Tissue Diagnostics (Ventana Medical Systems, Inc.) business…https://www.gesundheitsindustrie-bw.de/en/article/press-release/roche-acquires-mtm-laboratories-ag-expanding-offering-in-cervical-cancer
Article - 04/07/2011 Gingiva grown in Petri dishes We use teeth to break down food and gum disease is the major cause of tooth loss. Our teeth are firmly anchored in the jaw bone and surrounded and supported by the gum (gingiva), one of the five types of tissue that make up the human periodontium. A complex interplay of biomolecules maintains homoeostasis, i.e. the natural balance, in the gum tissue. A team of researchers led by Prof. Dr. Pascal Tomakidi from the Freiburg University Medical…https://www.gesundheitsindustrie-bw.de/en/article/news/gingiva-grown-in-petri-dishes
Press release - 15/06/2011 immatics’ pivotal Phase III trial with IMA901: First patients with renal cell carcinoma are vaccinated immatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that the first patients have been vaccinated in the IMPRINT study, a pivotal Phase III trial with IMA901, the company’s lead cancer vaccine for the treatment of renal cell carcinoma (RCC).https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-pivotal-phase-iii-trial-with-ima901-first-patients-with-renal-cell-carcinoma-are-vaccinated
Press release - 09/06/2011 Blood Clotting and Bowel Cancer Risk People whose blood clots more easily than normal are more often affected by cancer. Scientists at the German Cancer Research Center have discovered that a number of variants of clotting factor genes have an influence on bowel cancer risk. They found out that carriers of a particular gene variant of clotting factor V have a bowel cancer risk that is six times higher than people who do not have this gene variant.https://www.gesundheitsindustrie-bw.de/en/article/press-release/blood-clotting-and-bowel-cancer-risk
Article - 23/05/2011 Alzheimer’s disease puzzle remains unsolved despite new findings and theories 105 years after the first description of the Alzheimers disease by the German neuropsychiatrist Alois Alzheimer the disease still remains a mystery. Around 25000 researchers worldwide are focusing on Alzheimers and are coming up with a broad range of theories and hypotheses on its pathogenesis and potential therapies.https://www.gesundheitsindustrie-bw.de/en/article/news/alzheimer-s-disease-puzzle-remains-unsolved-despite-new-findings-and-theories
Dossier - 07/02/2011 The era of personalised medicine is dawning A promising future does not easily disappear into thin air. This is certainly the case with the vision of personalised medicine. For many years, biomedical researchers have vaunted the potential benefits of their findings despite the fact that neutral observers do not think that personalised medicine will really take off within the next 15 or 20 years. Moreover personalised medicine is a controversial term. So what is the state of play right now?https://www.gesundheitsindustrie-bw.de/en/article/dossier/the-era-of-personalised-medicine-is-dawning
Press release - 26/01/2011 Uncovering the Genetics of Prostate Cancer Germany will contribute another project to the International Cancer Genome Consortium ICGC. Coordinated by the German Cancer Research Center and the University Medical Center Hamburg-Eppendorf physicians and molecular biologists will now start to investigate the genetic causes of early prostate cancer. https://www.gesundheitsindustrie-bw.de/en/article/press-release/uncovering-the-genetics-of-prostate-cancer-1
Article - 28/11/2010 Genedata facilitates search for biomarkers Biomarkers play a key role in testing the efficacy of a new drug or finding out adverse reactions to it. For reliable and quick results, modern laboratory methods are used to generate huge amounts of highly complex molecular data. The data then need to be efficiently analysed. The company Genedata, with headquarters in Basel (Switzerland) and offices throughout Europe, including a base in Konstanz (Germany), has developed the software system…https://www.gesundheitsindustrie-bw.de/en/article/news/genedata-facilitates-search-for-biomarkers
Article - 13/11/2010 Evidence in personalised medicine Personalised medicine is the potential capacity to systematically use information about an individual patient in order to select or optimise that patient’s therapeutic care and tailor individual preventive treatments. Biomarkers need to be used as objective parameters in order to determine a patient’s individual risk profile. The role that features detected by genetic tests play in the causal mechanism of diseases and whether they are suitable…https://www.gesundheitsindustrie-bw.de/en/article/news/evidence-in-personalised-medicine
Article - 13/09/2010 Sven Perner: a pathologist with the courage to carry out interdisciplinary research Dr Sven Perner from Tuebingen was recently awarded the newly created Württemberg Cancer Prize for his work that has made decisive contributions to the understanding of prostate cancer development. In addition the identification of a tumour-specific gene fusion might also be of great importance for other types of cancer. https://www.gesundheitsindustrie-bw.de/en/article/news/sven-perner-a-pathologist-with-the-courage-to-carry-out-interdisciplinary-research
Article - 30/08/2010 Diagnostics for the early detection of cervical cancer The Pap test is regarded as the most successful test for cancer ever, and has saved the lives of many women. However, the test is associated with several weaknesses. The Heidelberg-based in vitro diagnostics company mtm laboratories AG develops and commercialises highly sensitive and highly specific immunochemical tests that provide greater reliability. These tests have the potential to revolutionise the early detection of cervical cancer.https://www.gesundheitsindustrie-bw.de/en/article/news/diagnostics-for-the-early-detection-of-cervical-cancer
Press release - 24/06/2010 febit Announces Operational Restructuring febit today announced a restructuring as a consequence of its strategic focus on blood-based microRNA biomarker discovery febits major business development in 20092010 and on partnerships and intellectual property IP commercialization. The new focus includes the collaboration and provision of high-end services for clinical researchers in academia diagnostic companies and the pharma industry. The operational restructuring resulted in a reduction…https://www.gesundheitsindustrie-bw.de/en/article/press-release/febit-announces-operational-restructuring
Press release - 02/06/2010 Meet and Match Event: Biomarker Last 26th of May in Mulhouse (France), 35 players of the industrial and academic domain experienced our first Meet&Match with the thematic: biomarkers. 14 speakers coming from all over the trinational BioValley presented their work during 12 minutes in front of a highly qualified and interested audience. https://www.gesundheitsindustrie-bw.de/en/article/press-release/meet-and-match-event-biomarker
Press release - 06/05/2010 Second Biomarker Expert Meeting in Heidelberg Numerous experts in molecular diagnostics convened at the Second Workshop of the Biomarker Discovery Center (BDC) in Heidelberg. More than 40 researchers from universities, hospitals and industry from various regions of Germany made their way to the city despite adverse travel conditions caused by the volcanic ash cloud.https://www.gesundheitsindustrie-bw.de/en/article/press-release/second-biomarker-expert-meeting-in-heidelberg
Article - 29/04/2010 The biopharmaceutical industry remained stable in times of crisis The German biopharmaceutical industry has come through 2009 without experiencing too many major slumps. The roaring growth of the biopharmaceutical industry in previous years has been replaced by more moderate growth. This is the result published by the 4th Medical Biotechnology report in 2010 compiled on behalf of the biotech interest group of the vfa bio Association of Research-Oriented Pharmaceutical Companies by the Boston Consulting Group. https://www.gesundheitsindustrie-bw.de/en/article/news/the-biopharmaceutical-industry-remained-stable-in-times-of-crisis
Press release - 23/04/2010 febit Receives European Union (EU) Patent for Synthesis of Minimal Genomes febit announced the receipt of an EU patent EP 1 728 860B1 for its technology to synthesize minimal genomes. The new patent protects febits technology for combining genes to construct a minimal functional genome or parts of it. The EU patent complements earlier patents on the synthesis of oligonucleotides for gene-assembling. https://www.gesundheitsindustrie-bw.de/en/article/press-release/febit-receives-european-union-eu-patent-for-synthesis-of-minimal-genomes
Press release - 12/03/2010 mtm laboratories announces the European launch of CINtec® PLUS mtm laboratories, a privately held diagnostics company from Heidelberg, Germany, announced the launch of CINtec® PLUS, the company’s next generation cervical cancer screening product with unmatched accuracy for the screening and management for cervical cancer. CINtec® PLUS will be launched with claims direct in Germany, Italy, Spain, France and the UK, and will also be available in other parts of the world via mtm’s nominated distributors.https://www.gesundheitsindustrie-bw.de/en/article/press-release/mtm-laboratories-announces-the-european-launch-of-cintec-plus
Article - 25/02/2010 Molecular marker for the treatment of lung cancer Whether the treatment of lung cancer with therapeutic antibodies is successful or not largely depends on the genetic makeup of the tumour. There is a need for reliable biomarkers that can predict patients’ response to treatment.https://www.gesundheitsindustrie-bw.de/en/article/news/molecular-marker-for-the-treatment-of-lung-cancer
Article - 25/01/2010 Intelligent use of suitable biomarkers How quickly does a pharmaceutical substance exert its effect? What mechanisms does it use to exert its effect on people and how long does it remain active? In a team headed by Prof. Dr. Martin Elmlinger Nycomed GmbH has developed an efficient biomarker discovery concept specially adapted to the companys requirements and designed to clarify such questions. The concept is specifically geared to the phases and requirements of the companys projects.…https://www.gesundheitsindustrie-bw.de/en/article/news/intelligent-use-of-suitable-biomarkers
Press release - 17/12/2009 Germany Starts Its Part in the International Cancer Genome Project German scientists will participate in the largest and most ambitious biomedical research project since the Human Genome Project. Coordinated by the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), the German participants of the International Cancer Genome Consortium (ICGC) will start their work in early January. Their aim is to analyze the molecular causes of childhood brain tumors. https://www.gesundheitsindustrie-bw.de/en/article/press-release/germany-starts-its-part-in-the-international-cancer-genome-project
Press release - 14/10/2009 mtm laboratories Extends Series C Financing Round by EUR 7 Million Bringing Total to EUR 39 Million (USD 57 Million) mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing in vitro diagnostics for cervical cancer early detection and diagnosis, announced on 14th October the signing for an additional tranche of Euro 7 million to its Series C funding. This addition is a formal expansion of the Company’s last Series C in March 2008 and increases the total for the round to Euro 39 million (USD 57 million) in…https://www.gesundheitsindustrie-bw.de/en/article/press-release/mtm-laboratories-extends-series-c-financing-round-by-eur-7-million-bringing-total-to-eur-39-million
Press release - 13/10/2009 Polyclone partners with Innovendia Consulting in Germany and Europe European biotech-platform and drug discovery companies will have easier access to Polyclone Bioservices assay design and validation services through its newly announced partnership with Innovendia Consulting from Owingen. EU and national government funded consortia will benefit from the more immediate availability of Polyclones unique combination of in vitro in silico assay design and validation capabilities. https://www.gesundheitsindustrie-bw.de/en/article/press-release/polyclone-partners-with-innovendia-consulting-in-germany-and-europe
Press release - 14/09/2009 Launch of SAFE-T Consortium: Translational Safety Biomarkers "Faster Development of Safer Medicines through Translational Safety Biomarkers": On September 14, 2009, the Safer And Faster Evidence-based Translation (SAFE-T) consortium project under the EU Innovative Medicines Initiative - Joint Undertaking (IMI-JU) was presented at the EUROTOX 2009 conference in Dresden. The consortium announces the start of work to qualify biomarkers for drug-induced kidney, liver and vascular injury in…https://www.gesundheitsindustrie-bw.de/en/article/press-release/launch-of-safe-t-consortium-translational-safety-biomarkers
Article - 14/09/2009 SensScreen Technologies: Magnetic separation to conquer biotechnological areas of application In terms of protein purification, the biopharmaceutical industry is increasingly reaching its technical and economic limits. The currently used chromatography procedures are expensive, time-consuming and associated with high product losses due to the large number of individual processing steps involved. Special magnetic microparticles, such as those developed by the chemist Dr. Jochen F. Peter with his recently established company SensScreen…https://www.gesundheitsindustrie-bw.de/en/article/news/sensscreen-technologies-magnetic-separation-to-conquer-biotechnological-areas-of-application
Press release - 10/08/2009 Biomarkers help predict the risk of Alzheimer’s in patients with mild cognitive impairment A large multicentre study has shown that CSF (cerebrospinal fluid) biomarkers can be used to predict, with good accuracy, as to which patients with mild cognitive impairments will develop Alzheimer’s disease. The biomarkers used are microtubule-associated proteins that are abundant in CNS neurons as well as beta amyloid, which is a peptide that forms brain plaques in people with Alzheimer’s disease. Changes in the concentrations of these proteins…https://www.gesundheitsindustrie-bw.de/en/article/press-release/biomarkers-help-predict-the-risk-of-alzheimer-s-in-patients-with-mild-cognitive-impairment
Article - 06/08/2009 PEPperPRINT wins award for its peptide chips PEPperPRINT GmbH, a spin-off of the German Cancer Research Centre, has won the Science4Life Venture Cup, a German start-up contest that comes with the most prize money. The Heidelberg-based start-up company was previously awarded the renowned research prize by the German Stifterverband and was chosen as a “Landmark in the Land of Ideas” competition run by the German government in 2009.https://www.gesundheitsindustrie-bw.de/en/article/news/pepperprint-wins-award-for-its-peptide-chips
Press release - 04/08/2009 Scientists open doors to diagnosis of emphysema Chronic inflammatory lung diseases like chronic bronchitis and emphysema are a major global health problem, and the fourth leading cause of death and disability in developed countries, with smoking accounting for 90% of the risk for developing them. Work by scientists at the European Molecular Biology Laboratory (EMBL) and its Molecular Medicine Partnership Unit (MMPU) with the University of Heidelberg, Germany, has shed new light on the…https://www.gesundheitsindustrie-bw.de/en/article/press-release/scientists-open-doors-to-diagnosis-of-emphysema
Press release - 23/07/2009 First Catalog Cancer Biochip for Sequence Capture Now Available from febit febit holding gmbh announced today the launch of the first human cancer biochip for HybSelectâ, febit’s highly automated technology for sequence capture, enabling targeted Next-Generation Sequencing (NGS). The new catalog cancer biochip features 115 important genes which are reported to be associated with common types of cancer by the Wellcome Trust Sanger Institute. https://www.gesundheitsindustrie-bw.de/en/article/press-release/first-catalog-cancer-biochip-for-sequence-capture-now-available-from-febit
Press release - 22/06/2009 Successful start: cooperative projects of the Rhine-Neckar Biotechnology Cluster (BioRN) The first joint public appearance of the numerous players of the BioRN top cluster underlines the importance of cooperations between industry and science. At the first annual BioRN conference the Cell-based and molecular medicine top cluster announced the successful start of five cooperative projects funded by the German Federal Ministry of Education and Research. In a strategy workshop the companies involved in the projects presented all 36…https://www.gesundheitsindustrie-bw.de/en/article/press-release/successful-start-cooperative-projects-of-the-rhine-neckar-biotechnology-cluster-biorn
Press release - 10/06/2009 6.56 million euros for first full-body PET-MRI prototype The Joint Science Conference in Bonn has announced that the University of Tübingen will receive 6.56 million euros for the purchase of an entirely new multimodal full-body tomography system for the diagnosis of cancer. The new full-body PET-MRI combines positron emission tomography PET with magnetic resonance imaging MRI in one device.https://www.gesundheitsindustrie-bw.de/en/article/press-release/6-56-million-euros-for-first-full-body-pet-mri-prototype
Article - 15/05/2009 Diabetes: we cannot wait any longer, we must act now! The renowned endocrinologist Prof. Bernhard Böhm from Ulm, like many of his colleagues, is of the opinion that diabetes is a problem that concerns society as a whole. The following interview with the head of endocrinology at the University Hospital of Ulm shows why the USA invests 50 times more money into diabetes research and Böhm tells us about the three wishes he would ask of a “diabetes fairy”.https://www.gesundheitsindustrie-bw.de/en/article/news/diabetes-we-cannot-wait-any-longer-we-must-act-now
Article - 20/04/2009 Programmed cell death and its role in cancer The closing symposium of the “Apoptosis Deficiency” funding priority of the German Cancer Aid Dr. Mildred Scheel Foundation was held in the German Cancer Research Centre in Heidelberg at the end of March 2009. German Cancer Aid has supported this programme since 1999 with over 15 million euros in funding. A total of 29 research groups at many German institutes and hospitals have received funding.https://www.gesundheitsindustrie-bw.de/en/article/news/programmed-cell-death-and-its-role-in-cancer
Article - 20/04/2009 Biomarkers for the identification of metastases Prof. Dr. Heike Allgayer a surgeon and molecular biologist from Heidelberg is investigating the molecular processes of the formation of tumour metastases. A major objective of her research is to find specific biomarkers that enable the early identification of metastases and to monitor the outcome of therapy. She has already received numerous prizes for her achievements.https://www.gesundheitsindustrie-bw.de/en/article/news/biomarkers-for-the-identification-of-metastases
Article - 19/03/2009 BioTeSys: isolate, characterise, analyse Bioactive substances are the speciality of BioTeSys GmbH an Esslingen-based biotech company. The company works with a range of products including cosmetics plant and berry extracts and low-dosage non-prescription food supplements. BioTeSys investigates the efficacy of the active ingredients of such products as well as the raw materials used to manufacture them. https://www.gesundheitsindustrie-bw.de/en/article/news/biotesys-isolate-characterise-analyse
Article - 10/01/2009 Julia Kirchheiner searches for drugs for individuals Drugs for individuals rather than diseases - thats what Julia Kirchheiner from the University of Ulm is striving for. The 37-year-old is one of only a handful German experts working in pharmacogenetics research a field of research that investigates the genetic causes of individual differences in peoples response to drugs. https://www.gesundheitsindustrie-bw.de/en/article/news/julia-kirchheiner-searches-for-drugs-for-individuals
Article - 06/12/2008 Strategic alliance between DKFZ and Bayer The German Cancer Research Centre and Bayer Schering Pharma AG signed an agreement to establish a strategic research alliance. The partners will invest a total of 3.5 million euros in cooperative cancer research over the next two years.https://www.gesundheitsindustrie-bw.de/en/article/press-release/strategic-alliance-between-dkfz-and-bayer
Article - 03/12/2008 Esslingen scientists to recalculate human age The actual age of a person not only depends on the date he or she was born. Biological age, which is far more important in determining lifespan, can so far only be estimated rather than precisely calculated. The European MARK-AGE research project is working on finding a solution to this problem. Esslingen plays a major role in this project for two reasons: the structure of the city and the company BioTeSys.https://www.gesundheitsindustrie-bw.de/en/article/news/esslingen-scientists-to-recalculate-human-age
Article - 29/11/2008 Telomeres and stem cells - Building blocks associated with ageing Prof. Dr. Lenhard Rudolph a well-known stem cell researcher at Ulm University is investigating the relationships between telomeres stem cell ageing and diseases. In the following interview with Walter Pytlik BioRegion Ulm Rudolph gives insights into state-of-the-art ageing research and its potential applications.https://www.gesundheitsindustrie-bw.de/en/article/news/telomeres-and-stem-cells-building-blocks-associated-with-ageing
Article - 16/11/2008 Looking for a formula to determine biological age The Europe-wide MARK-AGE project involving scientists from 14 countries commenced on the 1st April 2008. Scientists have joined forces to investigate the factors involved in ageing. They are using standardised questionnaires and analysing data acquired from physical and biochemical examinations of the blood and urine from 3700 volunteers. The team of experts includes the medical expert Professor Alexander Bürkle and the mathematician Prof.…https://www.gesundheitsindustrie-bw.de/en/article/news/looking-for-a-formula-to-determine-biological-age
Press release - 04/09/2008 Rhine Neckar Biotechnology Cluster wins German Top Cluster Contest The Rhine-Neckar biotechnology cluster BioRN was distinguished as one of the five most significant high-tech regions in Germany and will receive part of the 200 million Euro federal grant. https://www.gesundheitsindustrie-bw.de/en/article/press-release/rhine-neckar-biotechnology-cluster-wins-german-top-cluster-contest
Article - 25/08/2008 Markers that reveal the correct biological age Researchers at the University of Ulm have just identified a number of proteins that reveal the biological age of a person. These biomarkers might be used in medical applications to adapt the medical treatment of older people to their individual biological age.https://www.gesundheitsindustrie-bw.de/en/article/news/markers-that-reveal-the-correct-biological-age
Press release - 02/07/2008 Life-saving look at the blood flow Experienced medical physicists are able to detect everything without needing an operating table or a scalpel to construct a detailed picture of a patient’s cardiovascular system. Dr. Michael Markl is one of these experts, who nevertheless require top technological equipment, i.e. magnetic resonance imaging (MRI), to gain comprehensive insights into the vascular system. https://www.gesundheitsindustrie-bw.de/en/article/press-release/life-saving-look-at-the-blood-flow
Press release - 25/05/2008 Biosensor for measuring stress in cells Scientists at the German Cancer Research Centre DKFZ have developed a biological measuring system for determining the oxidation state of living cells. The system enables researchers to directly observe oxidation state variations accompanying biological processes.https://www.gesundheitsindustrie-bw.de/en/article/press-release/biosensor-for-measuring-stress-in-cells
Article - 02/05/2008 European-wide search for biomarkers of ageing Physical activity healthy nutrition more relaxation and no permanent sleep deficiency - is there a secret recipe for eternal youth? Alexander Bürkle from Constance along with scientists from all over Europe are aiming to identify the powerful biomarkers of human ageing.https://www.gesundheitsindustrie-bw.de/en/article/press-release/european-wide-search-for-biomarkers-of-ageing
Article - 05/04/2008 Successful cooperation between science and industry (II) In the second article in the series on the platforms successful cooperations BioValley presents an encouraging approach for improving the quality of life of severely ill cancer patients and the successful establishment of an industrial biochip platform. https://www.gesundheitsindustrie-bw.de/en/article/news/successful-cooperation-between-science-and-industry-ii
Article - 16/02/2008 New test for the early diagnosis of cervical cancer mtm laboratories has launched the Cervatec assay for the early diagnosis of cervical cancer. The Cervatec assay will initially be commercialized as an adjunct to the Pap test for the screening of women aged 35 and younger.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-test-for-the-early-diagnosis-of-cervical-cancer
Article - 10/02/2008 4th Biomarker Workshop at the NMI in Reutlingen: another success The Biomarker Workshop held at the NMI in late January has become a fixed date for a growing number of proteomics researchers. With an attendance of 130 this years workshop exceeded all previous ones. Those who were keen to find out more about the latest trends and findings were presented with a successful mix of basic and applied research information.https://www.gesundheitsindustrie-bw.de/en/article/news/4th-biomarker-workshop-at-the-nmi-in-reutlingen-another-success
Article - 28/01/2008 Funding programme "Medical systems biology - MedSys" Proposals must be submitted prior to 7th May 2008.https://www.gesundheitsindustrie-bw.de/en/article/press-release/funding-programme-medical-systems-biology-medsys